Incidence of uveal melanoma in the United States: 1973–1997

Singh, Arun D.; Topham, Allan

doi:10.1016/s0161-6420(03)00078-2

Cited by 453 publications

(313 citation statements)

References 22 publications

Supporting

Mentioning

268

Contrasting

Unclassified

Order By: Relevance

“…26,27 Contrary to previous reports, which have shown a slight predominance of males, 28 we found no statistically significant differences in the crude or age-adjusted incidence rates between genders. Although not fully comparable, the annual incidence of ocular melanoma in Norway has been reported to be 7.0 for women and 9.0 for men, 29 which indicates that the incidence of uveal melanoma has been relatively stable over the past several decades.…”

Section: Discussioncontrasting

confidence: 99%

Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation

Krohn

Monge

Skorpen

et al. 2007

Eye

View full text Add to dashboard Cite

Purpose To study the incidence, clinical findings, and tumour characteristics of posterior uveal melanoma in Western Norway, and to report the results of a consistent treatment strategy (I-125 brachytherapy or primary enucleation) over a 13-year period. Methods The clinical records of all patients with posterior uveal melanoma referred between January 1993 and December 2005 were reviewed. Clinical data, radiation parameters, visual outcome, and mortality were analysed in a dedicated database. Results The study included 111 consecutive patients. The annual age-adjusted incidence (per million population) of posterior uveal melanoma was 8.5 for women and 8.9 for men. Fifty-six patients underwent I-125 brachytherapy, 52 were enucleated, and three received no treatment. The median follow-up time was 36 months (mean, 52 months; range, 2 months to 13 years). In the brachytherapy group, two eyes were enucleated owing to tumour recurrence and two because of neovascular glaucoma. A visual acuity of 0.1 or better, present in 87% of the patients before brachytherapy, was retained in 40% after a median follow-up of 61 months. After brachytherapy, the 5-and 10-year melanomaspecific mortality rates were 13.4 and 23.8%, respectively. The corresponding mortality rates for patients treated with primary enucleation were 49.5 and 49.5%. Conclusion After brachytherapy, many patients lost useful vision due to radiationinduced complications. The probability of retaining the eye was high and only two patients experienced recurrent tumour growth. The mortality rates compare well with published series, and the differences in tumour size explain the difference in mortality between the two treatment groups.

show abstract

Section: Discussioncontrasting

confidence: 99%

Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation

Krohn

Monge

Skorpen

et al. 2007

Eye

View full text Add to dashboard Cite

show abstract

“…Mortality, however, has not been affected. 2 Forty to fifty per cent of all patients will still die of metastatic disease 3 within 9-10 years following diagnosis, despite early diagnosis of the primary tumour, successful local treatment, and close follow-up for the detection of metastasis. Life expectancy upon diagnosis of metastasis is extremely poor owing to the limited success of systemic therapy.…”

Section: Introductionmentioning

confidence: 99%

Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study

Callejo

Antecka

Blanco

et al. 2006

Eye

View full text Add to dashboard Cite

Purpose Most uveal melanoma patients (UMP) do not show evidence of metastases upon diagnosis. However, despite local tumour control, B50% of them will develop metastases. These findings suggest that malignant cells may have already disseminated by the time of initial diagnosis. The purpose of the study was to detect circulating malignant cells (CMCs) in UMP and to correlate them with prognostic factors and therapy. Methods Nested reverse transcriptasepolymerase chain reaction (RT-PCR) was used to detect CMCs. In each UMP, blood was collected every 3 months. In each visit, 20 RT-PCR tests were performed. The date of diagnosis, largest tumour dimension, type, and date of treatment were obtained. Results A total of 30 UMP were enrolled. Five patients were enrolled at the time of diagnosis and 25 patients between 1 and 17 years following diagnosis. No UMP showed clinical evidence of metastasis. A total of 136 visits were registered, 1360 samples collected, and 2720 RT-PCRs performed. CMCs were identified in 29 patients in 119 visits (87.5%). However, in each visit, a low number of positive tests were recorded. CMCs were found in newly diagnosed, irradiated, enucleated, and observed patients regardless of tumour size and time period following treatment. Conclusions Uveal melanoma (UM) is not a localized ocular disease. CMCs were recorded at initial diagnosis confirming the early metastatic nature of UM. CMCs were present following treatment, including enucleation, demonstrating that CMCs are capable of disseminating and surviving, possibly as micrometastasis, which would contribute to the pool of CMCs at a later stage. Systemic therapy should be evaluated.

show abstract

“…1 They are the most common intraocular tumours of adults, having an annual incidence in the western world of 0.8 cases per 100 000 population, 2 and are highly aggressive, frequently metastasising to the liver. Once hepatic metastases are established, survival is usually less than 12 months.…”

Section: Introductionmentioning

confidence: 99%

Multiple locations on chromosome 3 are the targets of specific deletions in uveal melanoma

Cross

Ganesh

Parpia

et al. 2005

Eye

View full text Add to dashboard Cite

Incidence of uveal melanoma in the United States: 1973–1997

Cited by 453 publications

References 22 publications

Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation

Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation

Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study

Multiple locations on chromosome 3 are the targets of specific deletions in uveal melanoma

Contact Info

Product

Resources

About